Wind显示，2025年上半年，158家企业挂牌新三板，其中6月新增挂牌企业13家。7月1日至13日，新增 挂牌企业6家。此外，截至7月13日，共有141家企业处于审查环节。 事实上，北交所开市以后，新三板挂牌企业数量稳步增长，2021年-2024年，新三板挂牌企业数量分别 为91家、270家、326家和350家。 业绩方面，Wind统计显示，158家新增挂牌企业最近一年营收规模的平均值9.75亿元，中位数是4.81亿 元，最近一年净利润平均值是6399.67万元，中位数是5331.49万元。净利润在6000万元以上的企业有58 家，净利润超过1亿元的企业有24家。 其中，净利润规模最大的企业是广州医药，公司5月20日在新三板挂牌。据介绍，广州医药成立于1951 年，距今已有70余年的经营历史，是一家以医药供应链服务为主的大型医药商业企业，是世界500强企 业广药集团大商业板块的核心企业。公司主要从事各类医药产品的批发及零售业务，并致力于向医药行 业价值链上下游的合作伙伴提供专业的供应链服务。目前，已发展为华南地区网络覆盖及终端规模领先 的医药商业企业，根据商务部发布的《药品流通行业运行统计分析报告》，202 ...

证券之星消息，截至2025年7月11日收盘，和顺石油(603353)报收于16.46元，上涨0.24%，换手率 2.09%，成交量3.56万手，成交额5829.33万元。 7月11日的资金流向数据方面，主力资金净流出851.96万元，占总成交额14.61%，游资资金净流出 366.16万元，占总成交额6.28%，散户资金净流入1218.12万元，占总成交额20.9%。 近5日资金流向一览见下表： | 指标 | 和顺石油 | 石油行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 28.54亿元 | 1838.39亿元 | 15 20 | | 净资产 | 1 16.62亿元 | 1831.71亿元 | 13 20 | | 净利润 | 1259.03万元 | 48.89亿元 | 15 20 | | 市盈率(动) | 56.67 | 26.51 | 11 20 | | 市净率 | 1.74 | 2.7 | 11 20 | | 毛利率 | 8.39% | 20.82% | 17 20 | | 净利率 | 1.64% | 15.25% | 14 20 | | ROE | 0. ...

Core Viewpoint - Metro Supply Chain Co., Ltd. has faced significant challenges in its attempts to go public on the Hong Kong Stock Exchange, marking its third unsuccessful attempt in five years, reflecting a decline in its business performance and market confidence [1][2]. Financial Performance - From 2021 to 2023, Metro Supply Chain's total revenue decreased from 27.82 billion to 24.86 billion, with net profits fluctuating at 332 million, -471 million, and 253 million respectively, indicating instability [3]. - For the first seven months of 2024, the company reported revenue of 14.82 billion, a slight decline of 1.0% year-on-year, with operating profit halved compared to the same period in 2023 [3]. Business Segments - The company operates primarily in four segments: retail distribution solutions, food service and distribution solutions, welfare gift solutions, and wholesale goods, with retail distribution solutions accounting for approximately 59.6% of total revenue in the first seven months of 2024 [3][4]. Client Dependency - Metro Supply Chain heavily relies on the Wumart Group, with sales to its top five clients constituting 64.0% of total revenue, and sales to Wumart alone accounting for over 96% of this amount [4][5]. Financial Health - The company has a high debt-to-asset ratio, consistently above 100%, and has seen its cash reserves drop significantly, with only 5.37 billion remaining as of July 31, 2024, a decrease of 64.4% year-on-year [7][8]. - The financial costs related to bank loans and non-trade payables have consumed a significant portion of its gross profit, with interest costs accounting for 67.0% and 73.5% of financial costs in 2023 and the first half of 2024 respectively [7]. Investor Pressure - Various venture capital and private equity investors, including IDG Capital and Tencent, are under pressure to exit their investments, with a potential redemption obligation of up to 15 billion USD if the company fails to go public by June 28, 2025 [8][9].

近日，麦德龙供应链有限公司（下称"麦德龙供应链"）的港股上市申请书失效，上市之路不确定性增 加，这也是其递交的第三份招股书失效。7月8日，南都湾财社记者向麦德龙供应链了解是否会重新递 表、港股上市计划是否有变动，麦德龙供应链相关负责人回应称，公司上市期间不便接受采访。 三次递交的港股招股书均失效 麦德龙供应链未能顺利闯关港股 麦德龙品牌起源于德国，1996年，其在上海开下了中国首家门店，做的是主要是B端生意，并以"会员 制""现购自运"模式经营。在外资品牌中，麦德龙表现强势。根据中国连锁经营协会发布的报告，2008 年，麦德龙在中国的销售额为126.46亿元，在连锁企业中排名第26名。彼时其仅有38家门店，单店收入 高达3.33亿元，远超过家乐福的2.52亿元和沃尔玛的2.26亿元。 然而，麦德龙并未能高歌猛进，和多个外资零售品牌一样，其后来上演的也是卖身的戏码。2019年10 月，物美集团宣布拿下了麦德龙中国80%股权，麦德龙中国被纳入物美阵营。在这一年，家乐福也被苏 宁易购收入囊中。 图源：企业官网 2021年3月29日，物美科技将物美超市业务和麦德龙中国打包，向港交所递交了上市申请，结果未能如 愿。对此 ...

中文天地出版传媒集团股份有限公司 CHINESE UNIVERSE PUBLISHING AND MEDIA GROUP CO., LTD. 公 司 章 程 （修订稿） 经公司 2024 年年度股东会审议通过 （2025 年 5 月 9 日） 目 录 第一章 总 则 核准江西鑫新实业股份有限公司重大资产出售及向江西省出版集团公司发行股 份购买资产的批复》，江西鑫新实业股份有限公司进行重大资产出售及向江西省 出版集团公司发行股份购买资产。本次重组完成后，江西鑫新实业股份有限公司 更名为中文天地出版传媒股份有限公司。 份有限公司更名为中文天地出版传媒集团股份有限公司。 第四条 公司根据《公司法》《党章》的规定，设立中国共产党中文天地出 版传媒集团股份有限公司委员会（以下简称公司党委），健全中国共产党的基层 组织体系，建立党的工作机构，配备党务工作人员，切实加强党的领导。公司应 为党组织正常开展活动提供必要条件。 第五条 公司注册名称： 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司 ...

Core Insights - The "Agricultural Products Wholesale Price 200 Index" increased to 112.64, up by 0.34 points from the previous Friday, indicating a rise in wholesale prices of agricultural products [1] - The "Vegetable Basket" product wholesale price index rose to 112.67, up by 0.39 points from the previous Friday, reflecting a similar trend in vegetable prices [1] Price Changes - The average price of pork reached 20.66 yuan/kg, an increase of 0.4% from the previous Friday [1] - Beef prices rose to 63.6 yuan/kg, also up by 0.4% [1] - Mutton prices decreased to 59.54 yuan/kg, down by 0.4% [1] - Egg prices increased slightly to 7.06 yuan/kg, up by 0.1% [1] - The price of white-feathered chicken rose to 17.14 yuan/kg, up by 0.1% [1] Vegetable and Fruit Prices - The average price of 28 monitored vegetables was 4.36 yuan/kg, an increase of 0.5% [1] - The average price of 6 monitored fruits was 7.33 yuan/kg, up by 0.4% [1] Fish Prices - The price of crucian carp was 22.77 yuan/kg, an increase of 0.7% [1] - Carp prices rose to 15.59 yuan/kg, up by 0.5% [1] - The price of white catfish decreased to 10.26 yuan/kg, down by 0.8% [1] - Large hairtail fish prices increased to 39.55 yuan/kg, up by 1.2% [1]

Core Insights - The recent surge in gold prices has led consumers to deliberate on whether to purchase gold, particularly for jewelry or investment purposes [1] - The current gold price is influenced by international market trends, interest rate expectations, and heightened risk aversion [4] Price Trends - Major gold retailers like Chow Tai Fook and Luk Fook are quoting prices between 1003-1005 yuan per gram, an increase of 5-7 yuan from previous prices [4] - China Gold's price is lower at 969 yuan per gram, allowing for significant savings when purchasing larger quantities [4] Price Differentiation - The price of jewelry gold is significantly higher than investment gold due to factors like craftsmanship, brand premium, and operational costs [5] - For example, a 10-gram gold chain from Chow Tai Fook costs approximately 10,050 yuan, while an equivalent investment gold bar costs around 7,850 yuan, highlighting a price difference of 2,200 yuan [5] Purchasing Strategies - For investment purposes, it is advisable to choose investment gold bars or wholesale gold, which have lower premiums and are closer to international gold prices [6] - For personal use or collection, consumers should compare prices across different brands to find the best deal [8] - For savings or appreciation, it is recommended to wait for a slight correction in international gold prices or to use a dollar-cost averaging strategy to mitigate investment risks [8] Timing for Purchase - Concerns about buying at a peak are valid, but high price levels do not necessarily indicate an imminent drop [9] - Gold investment should focus on long-term value preservation rather than short-term speculation [9] - If there is a pressing need and funds can be held long-term, short-term price fluctuations may be less impactful [9] Conclusion - The ongoing rise in gold prices necessitates careful consideration in purchasing decisions [10] - Consumers should align their gold product choices and timing with their specific needs to avoid unnecessary losses and achieve investment goals [10]

Core Viewpoint - Zhejiang Dongri, once a high-flying stock due to the "brain-computer interface" concept, saw its stock price plummet after clarifying that its main business is unrelated to this concept, leading to a significant market correction [1][2][4] Group 1: Stock Performance - From June 16 to June 27, Zhejiang Dongri's stock price surged for 10 consecutive trading days, with 6 days hitting the daily limit, resulting in a cumulative increase of 105.16% [2][3] - On June 30, the stock opened at 26.82 yuan, down 6.35%, and closed at the daily limit of 25.78 yuan, marking a decline of 9.99% [1] Group 2: Company Announcements - On June 27, Zhejiang Dongri issued a "Severe Abnormal Fluctuation Announcement," clarifying that its main business involves managing vegetable markets and selling tofu, with no connection to the "brain-computer interface" [1][2] - The company had previously issued multiple announcements, including a "Risk Warning Announcement," emphasizing that its daily operations do not involve the "brain-computer interface" business [3][4] Group 3: Market Manipulation Concerns - The stock's prior surge was characterized as speculative trading, with indications of potential market manipulation, especially given the company's clarifications about its business focus [2][3] - The misleading nature of the stock's rise based on the "brain-computer interface" concept has raised concerns about investor protection and the need for regulatory scrutiny [4]

Core Viewpoint - Nanjing Pharmaceutical has experienced significant growth since its listing in 1996, with its market capitalization increasing from 586 million yuan to 6.623 billion yuan, reflecting the development of the pharmaceutical distribution industry, although recent years show a slowdown in growth momentum [1][3]. Business Overview - The main business of Nanjing Pharmaceutical includes the sale of pharmaceutical products, with wholesale accounting for the highest revenue share at 94.72%, followed by retail at 4.53% [3]. - Since its listing, the company has achieved a cumulative net profit growth of 1788.12%, from 30 million yuan in 1996 to 571 million yuan in 2024, with 17 years of profit growth out of 29 years [3][4]. Financial Performance - Revenue has shown steady growth, increasing from 39.817 billion yuan in 2020 to 53.696 billion yuan in 2024, although the growth rate has been gradually slowing [4]. - The net profit attributable to shareholders rose from 37.6 million yuan in 2020 to 571 million yuan in 2024, with a slight decline in the last two years indicating increased competitive pressure in the industry [4]. Market Capitalization - Since its listing, Nanjing Pharmaceutical's market capitalization has increased by 10.30 times, demonstrating long-term investment value. However, it has decreased from a peak of 18.397 billion yuan in June 2015 to 6.623 billion yuan, representing a market value loss of 11.774 billion yuan or 64% [6].

Group 1 - The core viewpoint of the news highlights the significant stock price fluctuations of Zhejiang Dongri, which experienced a cumulative increase of 100% over ten consecutive trading days, driven by the hype surrounding brain-computer interface stocks due to recent clinical advancements by Neuralink [1] - Zhejiang Dongri's main business involves the operation and management of agricultural product wholesale markets, fresh food distribution, and tofu production, with no direct involvement in brain-computer interface technology [1] - As of the end of May 2025, Zhejiang Dongri's associated company, Peianmei (Zhejiang) Technology Co., Ltd., reported a total revenue of 28,700 yuan and a net loss of 661,400 yuan, indicating minimal impact on the company's overall performance [1] Group 2 - The speculative trading behavior surrounding certain stocks is driven by investors' desire for quick profits, leading to a false sense of trading activity and price increases, despite the lack of fundamental value [3] - The current trading environment is characterized by extreme volatility, where stocks can experience rapid price increases followed by sharp declines, often resulting in significant losses for ordinary investors [3] - As of the latest report, Zhejiang Dongri's stock is trading at 25.78 yuan per share, reflecting a decline of 9.99% [4]